

Investment Objective and Benchmark Index

The Biotech Growth Trust PLC (the “Company”) seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).




Portfolio Manager
Geoffrey Hsu

Portfolio Manager
Josh Golomb



Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.



— Share Price (total return) +29.3%
— Net Asset Value per share (total return) +27.1%
— Benchmark: NASDAQ Biotechnology Index (sterling adjusted) +33.1%

Source: Morningstar, Index - Bloomberg.

Ten Largest Holdings as at 30 June 2024 (% of total investments)

Name	Total
Amgen	9.3
Biogen	7.0
Regeneron Pharmaceuticals	5.3
Sarepta Therapeutics	5.2
Argenx	4.5
Ionis Pharmaceuticals	4.0
XtalPi (QuantumPharm)	3.6
Alnylam Pharmaceuticals	3.1
Janux Therapeutics	2.9
Syndax Pharmaceuticals	2.9
Total	47.8

Fast Facts	As at 30 June 2024
Launch Date	June 1997
AIC Sector	Biotechnology & Healthcare
	Date of Appointment of Orbimed 19 May 2005
Annual Management Fee (payable by the Company)	0.65% of net assets plus 0.30% per annum on the Company's market capitalisation up to £500m, 0.20% on market capitalisation above £500m to £1bn and 0.10% on market capitalisation over £1bn
Performance fee	See Annual Report for details
Ongoing Charges Ratio (OCR) *	1.2%
Continuation Vote	2025 AGM and every 5th AGM thereafter
Year / interim end	31 March / 30 September
Capital Structure	32,962,198 Ordinary Shares of 25p

Trust Characteristics

Number of Holdings	64
Net Assets (£m)	£351.8m
Market Capitalisation (£m)	£324.7m
Dividend Policy	It is not anticipated that the Company will pay a dividend
Gearing (AIC basis)	2.3%
Leverage**	Gross 105.1% Commitment 104.6%
Share Price (p)	985.00
NAV (p)	1,067.28
(Discount) / Premium	(7.7%)
Portfolio Turnover p.a.	108.0%
Active Share***	71.6%

Geographical Breakdown as at 30 June 2024 (%)†

North America	82.2%
China (quoted)	8.8%
Continental Europe	8.5%
Unquoted ‡	0.5%

Total **100.0%**

† Calculation based on economic exposure and expressed as a % of the total economic exposure. This includes all derivatives as an economically equivalent position in the underlying holding.

‡ No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. Of the 0.5% unquoted investments, 0.2% was in China and 0.3% was in Asia.

Source: All portfolio information sourced from Frostrow Capital LLP

Discrete Performance – Calendar Years (%)

Percentage Growth 12 Month Return	2019	2020	2021	2022	2023	YTD
NAV	47.4	52.4	-23.1	-13.6	-7.2	12.6
Share Price	48.5	67.7	-24.6	-22.1	-3.5	10.2
Index	19.6	22.1	0.2	-0.3	-1.7	5.0

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Jun 19-Jun 20	Jun 20-Jun 21	Jun 21-Jun 22	Jun 22-Jun 23	Jun 23-Jun 24
NAV	56.8	10.3	-39.1	-1.7	22.8
Share Price	63.3	13.2	-42.9	0.1	22.4
Index	28.6	7.5	-17.5	4.1	12.1

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed.

Source: NAV (total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg.

*Calculated at the financial year end, includes management fees and all other operating expenses, excludes performance fees.


**The Board has set the leverage limit for both the Gross and the Commitment basis at 130% of the Company's Net Asset Value.

***Active Share is expressed as a percentage and shows the extent to which a fund's holdings and their weightings differ from those of the fund's benchmark index. A fund that closely tracks its index might have a low Active Share of less than 20% and be considered passive, while a fund with an Active Share of 60% or higher is generally considered to be actively managed.

Investment Policy

In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. The Company's borrowing policy is that borrowings will not exceed 20% of value of the Company's net assets. The Company may be unable to invest directly or efficiently in certain countries or share classes. In these circumstances, the Company may gain exposure by investing indirectly through swaps or other derivative instruments. Exposure to these financial instruments will count towards and be subject to the following limits: Derivative transactions (excluding equity swaps) can be used to mitigate risk and/or enhance return and will be restricted to an aggregate net exposure of 5% of the value of the gross assets measured at the time of the relevant transaction; Equity swaps may be used for efficient portfolio management purposes and aggregate net counterparty exposure through a combination of derivatives and equity swap transactions is restricted to 12% of the value of the gross assets of the Company at the time of the transaction.

Return vs Volatility (Annualised since Date of Appointment of OrbiMed) – Chart (%)



Commentary

In June, the NAV per share was up 3.8%, the share price was up 4.3% and the benchmark NASDAQ Biotechnology Index (sterling adjusted) was up 4.0%.

Biotech and the general markets were broadly up in June. Fundamental news for the sector was generally positive during the month with favorable outcomes for three high-profile catalysts: 1) Alnylam Pharmaceuticals announced positive Phase 3 results for its drug vutrisiran for ATTR amyloidosis with cardiomyopathy, sending the shares up over 30%; 2) Sarepta Therapeutics succeeded in securing a label expansion for its gene therapy Elevidys for Duchenne muscular dystrophy despite a mixed data set; and 3) Avidity Biosciences announced positive Phase 1/2 data for its antibody oligonucleotide conjugate in facioscapulohumeral muscular dystrophy. The Company held shares in Sarepta and Avidity into these events. In addition, one of the Company's private Chinese companies, XtalPi, a leading technology company applying artificial intelligence and robotics to drug discovery, succeeded in going public on the Hong Kong exchange under the name QuantumPharm. With that IPO, the Company's remaining private holdings now consist of a small position in StemiRNA Therapeutics, a Chinese mRNA-based biotech company, and a legacy position in OrbiMed Asia Partners, an OrbiMed-managed Asia-focused venture capital fund. We intend to become more active in making private investments once the IPO market has strengthened further.

A couple of merger and acquisition ("M&A") transactions were announced in June. ANI Pharmaceuticals announced its acquisition of Alimera Sciences for \$381 million upfront, which gives ANI access to Iluvien, a drug used to treat diabetic macular edema and non-infectious posterior uveitis. AbbVie acquired Celsius Therapeutics, a privately held biotechnology company specializing in anti-inflammatory disease therapies, for \$250 million in a cash deal; the acquisition gives AbbVie access to Celsius' lead investigational drug candidate, CEL383, a potential first-in-class antibody that has completed a Phase 1 clinical study in inflammatory bowel disease. Neither of these M&A targets were held by the Company. While biopharma M&A activity slowed down towards the end of the second quarter, large pharma companies such as Merck, Roche, Bristol-Myers Squibb, and Novartis have reiterated their interest in bolt-on acquisitions at investor conferences in June.

Avidity Biosciences, Geron, and Sarepta Therapeutics were the largest positive contributors to performance during the month. Avidity's stock price appreciated after the company released proof-of-concept data for its drug, del-brax, that showed trends in functional improvement in patients with facioscapulohumeral muscular dystrophy, a disease characterized by progressive muscle loss in the face, shoulders, arms, and lower legs. Geron's stock surged after its drug Rytelo gained FDA approval to treat transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes. Sarepta outperformed in June after announcing expanded approval of Elevidys to treat Duchenne muscular dystrophy patients ages 4 and above.

Janux Therapeutics, ALX Oncology, and Lyell Immunopharma were the largest negative contributors to performance during the month. Janux underperformed as investors continued to take profits after rumors of a possible acquisition did not materialize. ALX Oncology's stock continued to sell off as investors de-risked ahead of gastric cancer data in July. Lyell underperformed following the release of Phase 1 data for its cellular therapy LYL797 in solid tumor patients, which showed some pulmonary toxicity.

Codes

Sedol	0038551
ISIN	GB0000385517
Legal Entity Identifier (LEI)	549300Z41EP32MI2DN29
Global Intermediary Identification Number (GIIN)	U1MQ70.99999.SL.826
Bloomberg	BIOG LN
EPIC	BIOG

Discount / Premium Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to NAV per share at which the shares trade to no more than 6%. Shares bought back will be cancelled.

How to Contact Us

Frostrow Capital LLP
 25 Southampton Buildings
 London, WC2A 1AL

Tel.: 0203 008 4910
 Fax: 0203 043 8889

Website: www.frostrow.com
 Email: info@frostrow.com

Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. Shares of the Company are bought and sold on the London Stock Exchange (LSE). The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it. For further information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.biotechgt.com. The Company can borrow to purchase investments, this could potentially magnify any losses or gains made by the Company.

Target Market

The Company is suitable for investors seeking an investment that aims to deliver total returns over the longer term (at least five years), is compatible with the needs for retail clients, professional clients and eligible counterparties, and is eligible for all distribution channels.

The Company may not be suitable for investors who are concerned about short-term volatility and performance, have low or no risk tolerance or are looking for capital protection, who are seeking a guaranteed or regular income, or a predictable return profile. The Company does not offer capital protection.

Value Assessment

Frostrow Capital LLP has conducted an annual Value Assessment on the Company in line with Financial Conduct Authority (FCA) rules set out in the Consumer Duty regulation. The Assessment focuses on the nature of the product, including benefits received and its quality, limitations that are part of the product, expected total costs to clients and target market considerations.

Within this, the assessment considers quality of services, performance of the Company (against both benchmark and peers), total fees (including management fees and entry and exit fees as applicable to the Company), and also considers whether vulnerable consumers are able to receive fair value from the product.

Frostrow Capital LLP concluded that the Company is providing value based on the above assessment.

Important Information

The Biotech Growth Trust PLC is a public limited company whose shares are premium listed on the LSE and is registered with HMRC as an investment trust. The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held in 2025).

This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the Financial Conduct Authority ("FCA").
